Hansa Biopharma AB

Q2 2026 total revenue was SEK 48.1 million, down 2% from SEK 49.1 million in Q2 2025. Product sales were SEK 46.8 million, down 2% from SEK 47.8 million in Q2 2025, but up 39% versus Q1 2026. SG&A was approximately SEK 119 million, up from SEK 91 million a year ago and up SEK 13 million versus Q1 2026, while R&D was approximately SEK 68 million, down 29% from Q2 2025. The loss from operations was SEK 174 million versus SEK 155 million in Q2 2025, and cash used in operations was SEK 104 million versus SEK 112 million a year ago. Cash and cash equivalents were SEK 553 million at quarter end, rising to about SEK 1.8 billion pro forma including the EUR 110 million SERB upfront payment. No formal next-quarter revenue guidance was given; management said the company is focused on the Dec. 19 PDUFA, launch readiness, and expected U.S. availability in Q1 2027 if approved.

Renée Aguiar-Lucander framed the quarter as transformative, pointing to the SERB partnership, the positive PAES readout, and the strengthening of the leadership team. She said the European partnering decision may create short-term financial pressure, but argued it is strategically right for patients and for Hansa. Her tone was confident and execution-focused, with repeated emphasis on being launch-ready and on a Q4 value inflection.

Adam Cutler highlighted that Q2 revenue was SEK 48.1 million, product sales were SEK 46.8 million, SG&A rose to about SEK 119 million due to U.S. launch preparation, the convertible debt, the SERB deal, and incentive programs, and R&D fell to about SEK 68 million as trial activity wound down. He said operating loss was SEK 174 million and cash used in operations was SEK 104 million. He also noted quarter-end cash of SEK 553 million, or about SEK 1.8 billion pro forma including the EUR 110 million SERB upfront, which he said extends runway and strengthens the balance sheet.

Analysts focused on the pace of FDA review ahead of the December PDUFA, and Renée said the interaction has been “very normal,” with consistent queries but nothing that caused concern. Questions on launch readiness centered on what can be done before approval; management said field teams are profiling the top transplant centers and assessing clinical, operational, and financial readiness. There were also questions on SERB accounting, commercial reimbursement, and the new HNSA-5487 program; management said SERB upfront revenue recognition may be spread over time, commercial coverage could start through contracted rates or single-case agreements, and HNSA-5487 remains in FDA discussions with an IND targeted before year-end.